Literature DB >> 11982859

Recognition of synthetic polypeptides corresponding to the N- and C-terminal fragments of Plasmodium falciparum Exp-1 by T-cells and plasma from human donors from African endemic areas.

Valentin Meraldi1, Issa Nebié, Rémy Moret, Nadine Cuzin-Ouattara, Ali Thiocone, Ogobara Doumbo, Fulvio Esposito, Alfred S Traoré, Giampietro Corradin, Silvia Terenzi.   

Abstract

The present work describes the recognition of three synthetic polypeptides encompassing the N- and C-terminal regions of the transmembrane Exp-1 protein of the parasite Plasmodium falciparum by plasma and peripheral blood mononuclear cells from naturally exposed individuals living in African endemic areas. The three polypeptides comprise the sequences 23-105, 73-162 and 101-162, and overlap at the transmembrane domain (73-105). Thus, they permitted characterization of the immune response specific to the N- and C-terminal domains in an independent fashion. Two different populations were evaluated, one in the village of Safo in Mali and the other in the villages of Somnaway, Kabortenga and Toussouktenga in Burkina Faso. Antibodies to the sequence 73-162 of Pf Exp-1 were found in 70% of adult Mali donors and in all of the donors tested from Burkina Faso. Strikingly, the N-terminal fragment Pf Exp-1 23-105 was only weakly recognized by a few donors. Evaluation of the T-cell response indicated that the peptide Pf Exp-1 23-105 was more potent than Pf Exp-1 73-162 in inducing a proliferative response. A correlation between peptide-specific interferon-gamma and interleukin-6 production and proliferation to peptide Pf Exp-1 23-105 was observed. Further studies are needed to evaluate this molecule as a vaccine candidate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11982859     DOI: 10.1046/j.1365-3024.2002.00447.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  5 in total

1.  Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites.

Authors:  Ruobing Wang; Thomas L Richie; Maria Fe Baraceros; Nancy Rahardjo; Tanya Gay; Jo-Glenna Banania; Yupin Charoenvit; Judith E Epstein; Thomas Luke; Daniel A Freilich; Jon Norman; Stephen L Hoffman
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

2.  High-density Peptide Arrays Help to Identify Linear Immunogenic B-cell Epitopes in Individuals Naturally Exposed to Malaria Infection.

Authors:  Thomas Jaenisch; Kirsten Heiss; Nico Fischer; Carolin Geiger; F Ralf Bischoff; Gerhard Moldenhauer; Leszek Rychlewski; Ali Sié; Boubacar Coulibaly; Peter H Seeberger; Lucjan S Wyrwicz; Frank Breitling; Felix F Loeffler
Journal:  Mol Cell Proteomics       Date:  2019-01-10       Impact factor: 5.911

3.  Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection.

Authors:  Joshua M Obiero; Seif Shekalaghe; Cornelus C Hermsen; Maxmillian Mpina; Else M Bijker; Meta Roestenberg; Karina Teelen; Peter F Billingsley; B Kim Lee Sim; Eric R James; Claudia A Daubenberger; Stephen L Hoffman; Salim Abdulla; Robert W Sauerwein; Anja Scholzen
Journal:  Infect Immun       Date:  2015-03-16       Impact factor: 3.441

4.  Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans.

Authors:  Anne C Teirlinck; Matthew B B McCall; Meta Roestenberg; Anja Scholzen; Rob Woestenenk; Quirijn de Mast; Andre J A M van der Ven; Cornelus C Hermsen; Adrian J F Luty; Robert W Sauerwein
Journal:  PLoS Pathog       Date:  2011-12-01       Impact factor: 6.823

5.  Detection of EXP1-Specific CD4+ T Cell Responses Directed Against a Broad Range of Epitopes Including Two Promiscuous MHC Class II Binders During Acute Plasmodium falciparum Malaria.

Authors:  Janna Heide; Nils H Wildner; Christin Ackermann; Melanie Wittner; Matthias Marget; Alessandro Sette; John Sidney; Thomas Jacobs; Julian Schulze Zur Wiesch
Journal:  Front Immunol       Date:  2020-01-22       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.